Medical device giant Medtronic releases 1-year results from its Symplicity HTN-2 trial of renal ablation as treatment for drug-resistant hypertension.
MASSDEVICE ON CALL — Renal ablation continues to look good as a treatment for drug-resistant hypertension after 1 year of follow-up, according to newly released results of Medtronic's (NYSE:MDT) Symplicity HTN-2 trial.
Researchers directed "short bursts of radio waves" at the nerves surrounding the kidneys, successfully lowering blood pressure for at least 6 months and up to 1 year, according to the American Heart Assn.
"Studies will soon determine whether this procedure can cure mild hypertension, producing permanent drug-free normalization of blood pressure," Murray Esler, professor and senior director of the Baker IDI Heart & Diabetes Institute in Australia, said in prepared remarks. "Based on the blood pressure declines achieved, reduction in heart attack and stroke rates of more than 40 percent is anticipated."
Hypertension, defined as blood pressure higher than 140/90 mm Hg, affects more than 78 million U.S. adults, and 9% of them fail to response to drugs, according to the press release.
Speed bumps as diagnostics
Researchers developed a questionnaire for healthcare providers monitoring patients in ambulances on the way to the emergency room, using a patient's reaction to speed bumps as an indication of whether the patient may have appendicitis.
Cyberonics plans to buy back an additional 1 million shares before the end of fiscal 2015.
Ventana, a Roche Group subsidiary, won 510(k) clearance from the Food & Drug Administration for...
TYRX touts expanded 510(k) clearance for its AIGISRx N antibacterial envelope, now cleared for use...
Wall Street analysts find opportunities for savvy investors looking to take advantage of the fallout...